INO – inovio pharmaceuticals, inc. (US:NASDAQ)

News

Inovio Pharmaceuticals (NASDAQ:INO) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
INOVIO to Participate in December Investor Conferences
Individual investors invested in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) lost 13% last week, institutions remained on the sidelines [Yahoo! Finance]
Inovio Pharmaceuticals (NASDAQ:INO) had its "overweight" rating reaffirmed by analysts at UBS Group AG.
Inovio Pharmaceuticals (NASDAQ:INO) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com